at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .
Company profile
Ticker
TWST
Exchange
Website
CEO
Emily Leproust
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Twist Bioscience Worldwide • Genome Compiler Corporation • Twist Bio Computing, LLC • Twist Pharmaceutical • Twist Bioscience Singapore PTE. LTD. • iGenomX International • Twist Bioscience Netherlands B.V. • AbX Biologics, Inc. ...
IRS number
462058888
TWST stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
7 Feb 24
10-Q
2024 Q1
Quarterly report
2 Feb 24
8-K
Twist Bioscience Reports Fiscal First Quarter 2024 Financial Results
2 Feb 24
ARS
2023 FY
Annual report to shareholders
5 Jan 24
DEF 14A
Definitive proxy
5 Jan 24
8-K
Twist Bioscience Appoints Adam Laponis as Chief Financial Officer
5 Jan 24
S-8
Registration of securities for employees
21 Nov 23
10-K
2023 FY
Annual report
21 Nov 23
8-K
Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results
17 Nov 23
S-8
Registration of securities for employees
24 Aug 23
Transcripts
TWST
Earnings call transcript
2024 Q1
2 Feb 24
TWST
Earnings call transcript
2023 Q4
17 Nov 23
TWST
Earnings call transcript
2023 Q3
4 Aug 23
TWST
Earnings call transcript
2023 Q2
5 May 23
TWST
Earnings call transcript
2023 Q1
3 Feb 23
TWST
Earnings call transcript
2022 Q4
18 Nov 22
TWST
Earnings call transcript
2022 Q3
5 Aug 22
TWST
Earnings call transcript
2022 Q2
6 May 22
TWST
Earnings call transcript
2022 Q1
4 Feb 22
TWST
Earnings call transcript
2021 Q4
22 Nov 21
Latest ownership filings
144
Notice of proposed sale of securities
23 Apr 24
4
Adam Laponis
11 Apr 24
144
Notice of proposed sale of securities
9 Apr 24
4
Patrick John Finn
4 Apr 24
4
William Banyai
4 Apr 24
4
Dennis Cho
4 Apr 24
4
Emily M. Leproust
4 Apr 24
4
Paula Green
4 Apr 24
144/A
Notice of proposed sale of securities (amended)
2 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 289.28 mm | 289.28 mm | 289.28 mm | 289.28 mm | 289.28 mm | 289.28 mm |
Cash burn (monthly) | 7.52 mm | 7.58 mm | 16.70 mm | 18.10 mm | 6.90 mm | 11.87 mm |
Cash used (since last report) | 51.49 mm | 51.92 mm | 114.39 mm | 123.93 mm | 47.26 mm | 81.31 mm |
Cash remaining | 237.79 mm | 237.36 mm | 174.89 mm | 165.35 mm | 242.02 mm | 207.97 mm |
Runway (months of cash) | 31.6 | 31.3 | 10.5 | 9.1 | 35.1 | 17.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 195 |
Opened positions | 31 |
Closed positions | 27 |
Increased positions | 57 |
Reduced positions | 63 |
13F shares | Current |
---|---|
Total value | 1.32 tn |
Total shares | 71.92 mm |
Total puts | 185.20 k |
Total calls | 106.90 k |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 6.79 mm | $137.48 bn |
BLK Blackrock | 6.08 mm | $123.19 bn |
Vanguard | 5.59 mm | $113.27 bn |
JPM JPMorgan Chase & Co. | 5.07 mm | $102.67 bn |
STT State Street | 4.00 mm | $81.04 bn |
Millennium Management | 3.81 mm | $77.28 bn |
William Blair Investment Management | 3.57 mm | $72.40 bn |
CMTDF Sumitomo Mitsui Trust | 3.48 mm | $70.58 bn |
Nikko Asset Management Americas | 3.48 mm | $70.45 bn |
Integrated Core Strategies | 3.05 mm | $71.76 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Apr 24 | Adam Laponis | Common Stock | Sell | Dispose S | No | No | 33.155 | 556 | 18.43 k | 74,444 |
2 Apr 24 | Green Paula | Common Stock | Sell | Dispose S | No | No | 32.736 | 229 | 7.50 k | 92,421 |
2 Apr 24 | Banyai William | Common Stock | Sell | Dispose S | No | No | 32.736 | 327 | 10.70 k | 345,986 |
2 Apr 24 | Finn Patrick John | Common Stock | Sell | Dispose S | No | No | 32.736 | 492 | 16.11 k | 178,380 |
2 Apr 24 | Dennis Cho | Common Stock | Sell | Dispose S | No | No | 32.736 | 129 | 4.22 k | 81,004 |
News
Analyst Scoreboard: 5 Ratings For Twist Bioscience
10 Apr 24
Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $40
10 Apr 24
Cathie Wood's Ark Continues Tesla Stock Buying Spree, Acquires Over $14M Worth Of Shares Amid Dip
28 Mar 24
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
26 Feb 24
Cathie Wood Trims Nvidia, Shopify Stakes To Pump Whopping $40M Into Pinterest Despite Q4 Revenue Miss
8 Feb 24
Press releases
Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations
28 Mar 24
Twist Bioscience to Present at Upcoming Investor Conferences
22 Feb 24
Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System
6 Feb 24
Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT
5 Feb 24
Twist Bioscience Reports Fiscal First Quarter 2024 Financial Results
2 Feb 24